Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227818 · ClinicalTrials.gov registry record · Phase 3
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
A Phase 3 study, sponsored by Neurocrine Biosciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
NCT07227818 is a Phase 3 study that is actively recruiting participants, run by Neurocrine Biosciences. The registered enrollment target is 560 participants.
The verdict
NCT07227818, a Phase 3 study, is actively recruiting participants, sponsored by Neurocrine Biosciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
Study Summary
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
Interventions
- DRUG Placebo
- DRUG NBI-1117568
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2029-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227818
The ClinicalTrials.gov registry entry for NCT07227818 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 560 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07227818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07227818 about?
NCT07227818 is a clinical study titled "Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia". The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
What is the current status of trial NCT07227818?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 2025-12-16. Estimated completion is 2029-07.
What interventions are being tested in trial NCT07227818?
The interventions under investigation include: Placebo (DRUG), NBI-1117568 (DRUG).
Who is sponsoring clinical trial NCT07227818?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.